[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634092":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":30,"responsibleParty":40,"collaborators":11,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":11,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Nadezhda Women's Health Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intrauterine PRP","EXPERIMENTAL",null,[13],"Biological: Platelet rich plasma (PRP)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","Platelet rich plasma (PRP)","The same day, within 1 hour of sample preparation, the PRP will be carefully introduced in the uterine cavity by catheter on day 2 after LH peak. 1.5 ml of the PRP solution will be administered. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Georgi Stamenov, MD","CONTACT","+359888269839","g.stamenov@abv.bg",{"name":27,"role":23,"phone":28,"phoneExt":11,"email":29},"Dimitar Parvanov, PhD","+359885944618","dimparvanov@abv.bg",[31],{"facility":5,"status":32,"city":33,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":11,"geoPoint":11,"contacts":37},"RECRUITING","Sofia","1330","Bulgaria","BG",[38,39],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"name":27,"role":23,"phone":28,"phoneExt":11,"email":29},{"type":41,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100634092","endometrial-immune-profile-changes-after-autologous-intrauterine-prp-treatment-100634092",false,"NCT07535190","Endometrial Immune Profile Changes After Autologous Intrauterine PRP Treatment","Prospective Study on Endometrial Immune Profile Changes After Autologous Intrauterine Platelet Rich Plasma (PRP) Treatment","Inclusion Criteria:\n\n* Participating in Assisted Reproduction Treatment\n* Having infertility\n* Having regular menstrual cycles\n* Embryo transfer of euploid embryos\n\nExclusion Criteria:\n\n* Uterine pathologies\n* Endometrial Bacterial infections\n* Active endometrial inflammation\n* Polycystic ovary syndrome\n* Cancer diagnostics\n* Positive HIV, HCV or HBV tests\n* Autoimmune diseases\n* Recent immune therapy","FEMALE","18 Years","50 Years",{"count":53,"type":54},50,"ESTIMATED","INTERVENTIONAL",[57],"NA","The success rate after treatment by in-vitro fertilisation (IVF) strongly depends on the endometrial receptivity, which in turn is strictly connected to the endometrial immune profile. IVF outcome is largely dependent upon endometrial immune cell ratios and their relationship with one another.\n\nDuring the last few years there are several studies and case reports for intrauterine PRP application in patients resulting in a thicker, regenerated endometrium and better immune cell population ratios.\n\nIn this project, the investigators aim to analyze the effect of autologous intrauterine PRP administration on the endometrial immune profile, endometrial thickness, selected hormone levels (E2, P4) during the mid-luteal phase and IVF outcomes (biochemical and clinical pregnancy).",[60,61],"IVF Patients","Female Infertility",[63,64,65],"PRP","endometrium","IVF outcomes","2026-04-14",{"date":68,"type":69},"2026-04-17","ACTUAL",{"date":71,"type":69},"2026-01-19",{"date":73,"type":54},"2028-06",{"name":5,"class":6},1]